PMC:7394275 / 1230-2579 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PMC-OGER-BB

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":773,"end":781},"obj":"Body_part"},{"id":"T2","span":{"begin":912,"end":917},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma264783"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"of aspergillosis, candidiasis, mucormycosis, or cryptococcosis as co-morbidities in COVID-19 patients.\n\nThe Global Popularity of COVID-19 and the Possibility of Fungal Co-infections\nAs the human-to-human transmitted disease, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been an emergency global public health events [1, 2]. Till May 18th, 2020, the COVID-19 has rapidly spread to 212 countries and caused nearly 5 million laboratory-confirmed cases and more than 310,000 deaths globally. Like SARS-CoV and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS-CoV-2 is responsible for lower respiratory infection and can cause Acute Respiratory Distress Syndromes (ARDS) [3]. Besides, the diffuse alveolar damage with severe inflammatory exudation, COVID-19 patients always have immunosuppression with a decrease in CD4 + T and CD8 + T cells [4]. Critically ill patients, especially the patients who were admitted to the intensive care unit (ICU) and required mechanical ventilation, or had a longer duration of hospital stays, even as long as 50 days, were more likely to develop fungal co-infections [5]. Hence, it is important to notice that COVID-19 patients can develop further fungal infections during the middle and latter stages of this disease, especially severely"}

LitCovid-PubTator

LitCovid-PD-MONDO

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T7","span":{"begin":189,"end":194},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T8","span":{"begin":198,"end":203},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T9","span":{"begin":334,"end":337},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T10","span":{"begin":426,"end":429},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T11","span":{"begin":878,"end":879},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T12","span":{"begin":892,"end":895},"obj":"http://purl.obolibrary.org/obo/PR_000001004"},{"id":"T13","span":{"begin":904,"end":907},"obj":"http://purl.obolibrary.org/obo/CLO_0053438"},{"id":"T14","span":{"begin":910,"end":917},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T15","span":{"begin":1067,"end":1068},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"of aspergillosis, candidiasis, mucormycosis, or cryptococcosis as co-morbidities in COVID-19 patients.\n\nThe Global Popularity of COVID-19 and the Possibility of Fungal Co-infections\nAs the human-to-human transmitted disease, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been an emergency global public health events [1, 2]. Till May 18th, 2020, the COVID-19 has rapidly spread to 212 countries and caused nearly 5 million laboratory-confirmed cases and more than 310,000 deaths globally. Like SARS-CoV and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS-CoV-2 is responsible for lower respiratory infection and can cause Acute Respiratory Distress Syndromes (ARDS) [3]. Besides, the diffuse alveolar damage with severe inflammatory exudation, COVID-19 patients always have immunosuppression with a decrease in CD4 + T and CD8 + T cells [4]. Critically ill patients, especially the patients who were admitted to the intensive care unit (ICU) and required mechanical ventilation, or had a longer duration of hospital stays, even as long as 50 days, were more likely to develop fungal co-infections [5]. Hence, it is important to notice that COVID-19 patients can develop further fungal infections during the middle and latter stages of this disease, especially severely"}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":168,"end":170},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_27638"}],"text":"of aspergillosis, candidiasis, mucormycosis, or cryptococcosis as co-morbidities in COVID-19 patients.\n\nThe Global Popularity of COVID-19 and the Possibility of Fungal Co-infections\nAs the human-to-human transmitted disease, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been an emergency global public health events [1, 2]. Till May 18th, 2020, the COVID-19 has rapidly spread to 212 countries and caused nearly 5 million laboratory-confirmed cases and more than 310,000 deaths globally. Like SARS-CoV and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS-CoV-2 is responsible for lower respiratory infection and can cause Acute Respiratory Distress Syndromes (ARDS) [3]. Besides, the diffuse alveolar damage with severe inflammatory exudation, COVID-19 patients always have immunosuppression with a decrease in CD4 + T and CD8 + T cells [4]. Critically ill patients, especially the patients who were admitted to the intensive care unit (ICU) and required mechanical ventilation, or had a longer duration of hospital stays, even as long as 50 days, were more likely to develop fungal co-infections [5]. Hence, it is important to notice that COVID-19 patients can develop further fungal infections during the middle and latter stages of this disease, especially severely"}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T10","span":{"begin":104,"end":181},"obj":"Sentence"},{"id":"T11","span":{"begin":182,"end":391},"obj":"Sentence"},{"id":"T12","span":{"begin":392,"end":555},"obj":"Sentence"},{"id":"T13","span":{"begin":556,"end":751},"obj":"Sentence"},{"id":"T14","span":{"begin":752,"end":922},"obj":"Sentence"},{"id":"T15","span":{"begin":923,"end":1182},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"of aspergillosis, candidiasis, mucormycosis, or cryptococcosis as co-morbidities in COVID-19 patients.\n\nThe Global Popularity of COVID-19 and the Possibility of Fungal Co-infections\nAs the human-to-human transmitted disease, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been an emergency global public health events [1, 2]. Till May 18th, 2020, the COVID-19 has rapidly spread to 212 countries and caused nearly 5 million laboratory-confirmed cases and more than 310,000 deaths globally. Like SARS-CoV and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS-CoV-2 is responsible for lower respiratory infection and can cause Acute Respiratory Distress Syndromes (ARDS) [3]. Besides, the diffuse alveolar damage with severe inflammatory exudation, COVID-19 patients always have immunosuppression with a decrease in CD4 + T and CD8 + T cells [4]. Critically ill patients, especially the patients who were admitted to the intensive care unit (ICU) and required mechanical ventilation, or had a longer duration of hospital stays, even as long as 50 days, were more likely to develop fungal co-infections [5]. Hence, it is important to notice that COVID-19 patients can develop further fungal infections during the middle and latter stages of this disease, especially severely"}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":667,"end":688},"obj":"Phenotype"},{"id":"T2","span":{"begin":709,"end":729},"obj":"Phenotype"},{"id":"T3","span":{"begin":765,"end":788},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0011947"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002098"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0033006"}],"text":"of aspergillosis, candidiasis, mucormycosis, or cryptococcosis as co-morbidities in COVID-19 patients.\n\nThe Global Popularity of COVID-19 and the Possibility of Fungal Co-infections\nAs the human-to-human transmitted disease, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been an emergency global public health events [1, 2]. Till May 18th, 2020, the COVID-19 has rapidly spread to 212 countries and caused nearly 5 million laboratory-confirmed cases and more than 310,000 deaths globally. Like SARS-CoV and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS-CoV-2 is responsible for lower respiratory infection and can cause Acute Respiratory Distress Syndromes (ARDS) [3]. Besides, the diffuse alveolar damage with severe inflammatory exudation, COVID-19 patients always have immunosuppression with a decrease in CD4 + T and CD8 + T cells [4]. Critically ill patients, especially the patients who were admitted to the intensive care unit (ICU) and required mechanical ventilation, or had a longer duration of hospital stays, even as long as 50 days, were more likely to develop fungal co-infections [5]. Hence, it is important to notice that COVID-19 patients can develop further fungal infections during the middle and latter stages of this disease, especially severely"}

2_test

{"project":"2_test","denotations":[{"id":"32737747-32015507-73473585","span":{"begin":385,"end":386},"obj":"32015507"},{"id":"32737747-32123347-73473586","span":{"begin":388,"end":389},"obj":"32123347"},{"id":"32737747-32910461-73473587","span":{"begin":748,"end":749},"obj":"32910461"},{"id":"32737747-32731000-73473588","span":{"begin":919,"end":920},"obj":"32731000"},{"id":"32737747-32598906-73473589","span":{"begin":1179,"end":1180},"obj":"32598906"}],"text":"of aspergillosis, candidiasis, mucormycosis, or cryptococcosis as co-morbidities in COVID-19 patients.\n\nThe Global Popularity of COVID-19 and the Possibility of Fungal Co-infections\nAs the human-to-human transmitted disease, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been an emergency global public health events [1, 2]. Till May 18th, 2020, the COVID-19 has rapidly spread to 212 countries and caused nearly 5 million laboratory-confirmed cases and more than 310,000 deaths globally. Like SARS-CoV and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS-CoV-2 is responsible for lower respiratory infection and can cause Acute Respiratory Distress Syndromes (ARDS) [3]. Besides, the diffuse alveolar damage with severe inflammatory exudation, COVID-19 patients always have immunosuppression with a decrease in CD4 + T and CD8 + T cells [4]. Critically ill patients, especially the patients who were admitted to the intensive care unit (ICU) and required mechanical ventilation, or had a longer duration of hospital stays, even as long as 50 days, were more likely to develop fungal co-infections [5]. Hence, it is important to notice that COVID-19 patients can develop further fungal infections during the middle and latter stages of this disease, especially severely"}

PMC:7394275 / 1230-2579 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7394275 / 1230-2579 JSON TXT